Headlines about Recro Pharma (NASDAQ:REPH) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Recro Pharma earned a news sentiment score of 0.02 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 44.9854611252907 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s rankings:
- -$0.75 EPS Expected for Recro Pharma Inc (REPH) This Quarter (americanbankingnews.com)
- Oppenheimer Weighs in on Recro Pharma Inc’s FY2022 Earnings (REPH) (americanbankingnews.com)
- Q3 2018 EPS Estimates for Recro Pharma Inc (REPH) Decreased by Analyst (americanbankingnews.com)
- Recro Pharma: Cautious Cheer Following Earnings (seekingalpha.com)
- Recro Pharma Inc (REPH) Receives Average Recommendation of “Buy” from Brokerages (americanbankingnews.com)
A number of equities research analysts have weighed in on the stock. ValuEngine raised shares of Recro Pharma from a “sell” rating to a “hold” rating in a report on Thursday, June 28th. Janney Montgomery Scott reduced their target price on shares of Recro Pharma from $21.00 to $11.00 and set a “fair value” rating on the stock in a report on Thursday, May 24th. Oppenheimer set a $18.00 target price on shares of Recro Pharma and gave the stock a “buy” rating in a report on Wednesday. Zacks Investment Research lowered shares of Recro Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, May 15th. Finally, BidaskClub raised shares of Recro Pharma from a “hold” rating to a “buy” rating in a report on Thursday, May 24th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $12.63.
Shares of NASDAQ:REPH traded down $0.12 during trading on Friday, reaching $5.89. The stock had a trading volume of 127,583 shares, compared to its average volume of 120,162. The company has a debt-to-equity ratio of 2.22, a quick ratio of 1.55 and a current ratio of 1.59. Recro Pharma has a 52 week low of $4.78 and a 52 week high of $13.05. The firm has a market cap of $124.52 million, a P/E ratio of -2.96 and a beta of -0.94.
Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.34) by $0.72. Recro Pharma had a negative net margin of 75.19% and a negative return on equity of 144.84%. The company had revenue of $21.74 million for the quarter, compared to analyst estimates of $16.81 million. sell-side analysts anticipate that Recro Pharma will post -2.52 earnings per share for the current year.
In other news, major shareholder Healthcare Master Fun Broadfin sold 188,000 shares of the company’s stock in a transaction on Thursday, May 24th. The shares were sold at an average price of $5.81, for a total value of $1,092,280.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 21.60% of the company’s stock.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Featured Article: Diversification in Your Portfolio
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.